Kala Bio (KALA) Accounts Payables (2016 - 2026)
Kala Bio's (KALA) quarterly Accounts Payables came in at $1.1 million in Q2 2026, up 73.56% year-over-year from $658000.0 in Q2 2025, and up 9.39% quarter-over-quarter from $1.0 million in Q1 2026.
Analysis
Kala Bio (KALA) Accounts Payables (2016 - 2026) Analysis & Trends
Kala Bio has disclosed Accounts Payables across 11 years of filings, most recently posting $1.1 million for Q2 2026.
- In Q2 2026, Accounts Payables rose 73.56% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $1.1 million (up 73.56% YoY), while the FY2025 annual figure was $986000.0, up 57.01% from the prior year.
- Accounts Payables came in at $1.1 million for Q2 2026 at Kala Bio, up from $1.0 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $10.5 million in Q2 2022 to a low of $628000.0 in Q4 2024.
- Average Accounts Payables over 5 years is $2.2 million, with a median of $925000.0 recorded in 2023.
- Year-over-year, Accounts Payables surged 270.68% in 2022 and slumped 92.79% in 2023.
- Over 5 years, Accounts Payables stood at $2.8 million in 2022, then slumped by 67.55% to $919000.0 in 2023, then plunged by 31.66% to $628000.0 in 2024, then soared by 57.01% to $986000.0 in 2025, then gained by 15.82% to $1.1 million in 2026.
- Per Business Quant data, the three most recent Accounts Payables figures were $1.1 million in Q2 2026, $1.0 million in Q1 2026, and $986000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 167.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Kala Bio | 7.80 Mn | 7.80 Mn | - | 1.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Mn |
| Mar 31, 2026 | 1.04 Mn |
| Dec 31, 2025 | 986,000.00 |
| Sep 30, 2025 | 917,000.00 |
| Jun 30, 2025 | 658,000.00 |
| Mar 31, 2025 | 931,000.00 |
| Dec 31, 2024 | 628,000.00 |
| Sep 30, 2024 | 711,000.00 |
| Jun 30, 2024 | 665,000.00 |
| Mar 31, 2024 | 732,000.00 |
| Dec 31, 2023 | 919,000.00 |
| Sep 30, 2023 | 787,000.00 |
| Jun 30, 2023 | 760,000.00 |
| Mar 31, 2023 | 997,000.00 |
| Dec 31, 2022 | 2.83 Mn |
| Sep 30, 2022 | 7.35 Mn |
| Jun 30, 2022 | 10.54 Mn |
| Mar 31, 2022 | 6.22 Mn |
| Dec 31, 2021 | 4.90 Mn |
| Sep 30, 2021 | 5.85 Mn |